Aprea Therapeutics Inc

NASDAQ:APRE   3:59:53 PM EDT
4.64
0.00 (0.00%)
Products, Regulatory

Aprea Therapeutics Announces Clinical Hold On Lymphoid Malignancy Program

Published: 08/12/2021 10:14 GMT
Aprea Therapeutics Inc (APRE) - Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program.
Aprea Therapeutics Inc - U.S. FDA Placed Clinical Hold on Clinical Trial Evaluating Eprenetapopt With Acalabrutinib Or With Venetoclax and Rituximab.
Aprea Therapeutics Inc - FDA's Concerns Referred to Safety and Efficacy Data From Phase 3 Mds Clinical Trial.